The disclosure relates to the field of medicine, in particular to the field of veterinary medicine. The disclosure specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (LAMAs)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD) in animals, preferably equines such as horses.

The disclosure relates to the field of medicine, in particular to the field of veterinary medicine. The disclosure specifically relates to muscarinic antagonists (including long acting muscarinic antagonists (LAMAs)) for the treatment of airway disease, such as pulmonary disease, preferably recurrent airway obstruction (RAO), summer pasture associated obstructive pulmonary disease (SPAOPD), and inflammatory airway disease (IAD) in animals, preferably equines such as horses.

A convenient and hygienic skin therapy system comprising an encaser, one or more therapeutic compositions, a sealing means and optional accessories is disclosed. A method of using such a skin therapy system is also provided. The skin therapy system and the use thereof provides an effective, efficient and safe therapeutic approach.

A convenient and hygienic skin therapy system comprising an encaser, one or more therapeutic compositions, a sealing means and optional accessories is disclosed. A method of using such a skin therapy system is also provided. The skin therapy system and the use thereof provides an effective, efficient and safe therapeutic approach.

A phytosanitary composition including at least one paraffinic hydrocarbon fraction that includes isoparaffins, normal paraffins and naphthenes, wherein the content by weight of naphthenes ranges from 10 to 50% in relation to the total weight of the composition, and the weight ratio of the normal paraffins to the isoparaffins is greater than or equal to 0.30, in a carrier suitable for the phytosanitary treatment of plants.

Compositions and methods for treatment, control, or prevention of skin conditions or skin diseases associated with microbial biofilms are provided. A topical formulation comprises a surfactant, pharmaceutically acceptable carrier, biocide, and weak acid and is effective to disrupt both the microbial biofilm defenses as well as the microbes within. The topical formulation is also provided as a multi-component system suitable for the application to human or animal skin or mucosa. Methods of administering the topical formulations to an individual having, or at risk for having, a skin disease or skin condition associated with a microbial biofilm are also disclosed.

Dental, vaginal and anal cream composed of exclusively natural active principles containing glycerides and Vitamin A and D, easily retained and preserved when in contact with the inflamed mucosa due to its adhesive mucosal base.

Dental, vaginal and anal cream composed of exclusively natural active principles containing glycerides and Vitamin A and D, easily retained and preserved when in contact with the inflamed mucosa due to its adhesive mucosal base.

A cream for treating the skin may include gray clay kaolin; sodium lauryl ether sulfate; blue tartrazine; sodium chloride; menthol; metabisulfite sodium; gelatin; mineral oil; olive oil; oil of cloves; water; green tea; honey; talc; and aloe vera. The cream may also include apple perfume, vitamin E, vitamin D, vitamin C, vitamin B2, vitamin B5, vitamin H, vitamin B6, and vitamin D. The cream may also include fatty acids.

A cream for treating the skin may include gray clay kaolin; sodium lauryl ether sulfate; blue tartrazine; sodium chloride; menthol; metabisulfite sodium; gelatin; mineral oil; olive oil; oil of cloves; water; green tea; honey; talc; and aloe vera. The cream may also include apple perfume, vitamin E, vitamin D, vitamin C, vitamin B2, vitamin B5, vitamin H, vitamin B6, and vitamin D. The cream may also include fatty acids.